Skip to main content

Advertisement

SpringerLink
Log in

Treatment of medical complications in patients with brain tumors

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Patients with primary brain tumors and those with cerebral metastases are at risk throughout their illness for several major medical problems, including vasogenic edema, seizures, and symptomatic venous thrombosis. In turn, the corticosteroids, anti-epileptic drugs, and anticoagulants used to treat these problems may produce significant adverse effects and result in important drug-drug interactions that may complicate chemotherapy. Although few Class I studies address any of these issues, guidelines can be offered to maximize quality of life and minimize hospital readmis-sions. Optimal management of brain edema involves minimizing corticosteroid use and tapering the steroid dose slowly to avoid steroid withdrawal symptoms. Prophylaxis of Pneumocystis pneumonia is necessary for patients requiring corticosteroids for more than 1 month. Anti-epileptic drugs (AEDs) should be avoided unless patients experi-ence seizures. If possible, non-CTY (P450) enzyme-inducing drugs should be chosen. AED levels should be obtained frequently during corticosteroid taper. Multimodality venous thrombosis prophylaxis should begin at the time of the original surgery with external leg compression and unfractionated subcutaneous heparin or a low molecular weight heparin (LMWH). Brain tumor patients with symptomatic venous thrombosis or pulmonary embolism can be anticoagulated safely with warfarin or with LMWH, and LMWHs are preferable from the standpoints of efficacy, safety, and convenience for long-term outpatient treatment of venous thrombosis. Clinicians should be aware of potential drug-drug interactions between prescribed AEDs and chemotherapy and pos-sible interactions with complementary and alternative therapies chosen by their patients. They also should be aware of interventions to minimize late sequelae of brain tumors and their treatment, including cognitive decline, depression, and increased stroke risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Kaal ECA, Vecht CJ: The management of brain edema in brain tumors. Curr Opin Oncol 2004, 16: 593–600. This is an excellent review of the use of osmotic, corticoster-oid, and novel treatments for brain edema.

    Article  PubMed  CAS  Google Scholar 

  2. Papadopoulos MC, Saadoun S, Davies DC, et al.: Emerg-ing molecular mechanisms of brain tumour oedema. Br J Neurosurg 2001, 15: 101–108.

    Article  PubMed  CAS  Google Scholar 

  3. Watling CJ, Cairncross JG: Acetazolamide therapy for symptomatic plateau waves in patients with brain tumors. Report of 3 cases. J Neurosurg 2002, 97: 224–226.

    Article  PubMed  CAS  Google Scholar 

  4. Vecht CJ, Hovestadt A, Verbiest HBC, et al.: Dose-effect relation of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 milligrams per day. Neurology 1994, 44: 675–680.

    PubMed  CAS  Google Scholar 

  5. Meyer G, Badenhoop K: Gluco-corticoid-induced insu-lin resistance and diabetes mellitus. Receptor, post receptor mechanisms, local cortisol action, and new aspects of anti-diabetes mellitus therapy. Med Klin 2003, 98: 266–270.

    Article  Google Scholar 

  6. Nielsen GL, Sorensen HT, Mellemkjoer L, et al.: Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: a reg-ister-based cohort study. Am J Med 2001, 111: 541–545.

    Article  PubMed  CAS  Google Scholar 

  7. Batchelor TT, Taylor LP, Thaler HT, et al.: Steroid myopathy in cancer patients. Neurology 1997, 48: 1234–1238.

    PubMed  CAS  Google Scholar 

  8. Mahindra A, Grossman S: The growing problem of Pneumocystis carinii pneumonia among HIV negative brain tumor patients. Neuro-oncol 2001, 3: 361.

    Google Scholar 

  9. Thomas CH, Limper AH: Pneumocystis pneumonia. N Engl J Med 2004, 350: 2487–2498. This is the most current authoritative review of pathology, diagnosis, and management of pneumocystis.

    Article  PubMed  CAS  Google Scholar 

  10. Kovacs JA, Gill VH, Meshnick S, et al.: New insights into transmission, diagnosis and drug treatment of Pneumocystis carinii pneumonia. JAMA 2001, 286: 2450–2460. Along with Thomas article above, provides good overview of rationale for preventive strategies in non-HIV patients.

    Article  PubMed  CAS  Google Scholar 

  11. Luyken C, Blumcke I, Fimmers R, et al.: The spectrum of long-term epilepsy-associated tumors: long-term sei-zure and tumor outcome and neurosurgical aspects. Epilepsia 2003, 44: 822–830.

    Article  PubMed  Google Scholar 

  12. Hoang-Xuan K, Capaelle L, Kujas M, et al.: Temozolo-mide as initial treatment for adults with low grade oli-godendroglioma or oligoastrocytoma and correlation with chromosome 1p deletion. J Clin Oncol 2004, 22: 3133–3138.

    Article  PubMed  CAS  Google Scholar 

  13. Glantz MJ, Cole BR, Forsyth PA, et al.: Practice parame-ter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: report of the Quality Stan-dards Subcommittee of the American Academy of Neurology. Neurology 2000, 54: 1886–1893. Prophylactic antiepileptic drugs do not reduce the frequency of seizures and are not indicated in brain tumor patients who have not experienced seizures.

    PubMed  CAS  Google Scholar 

  14. Forsyth PA, Weaver S, Fulton D, et al.: Prophylactic anti-convulsants in patients with brain tumour. Can J Neu-rol Sci 2003, 30: 106–112.

    Google Scholar 

  15. Vecht CH, Wagner GL, Wilms EB: Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neu-rol 2003, 2: 404–409. Excellent compendium of possible interactions among all types of chemotherapeutic agents.

    Article  CAS  Google Scholar 

  16. Cohen AD, Reichental E, Halevy S: Phenytoin-induced severe cutaneous drug reactions: suspected interac-tions with corticosteroids and H2-blockers. Isr Med Assoc J 1999, 1: 95–97.

    PubMed  CAS  Google Scholar 

  17. Bromfield EB: Epilepsy in patients with brain tumors and other cancers. Rev Neurol Dis 2004, 1(Suppl 1): S27-S33.

    PubMed  Google Scholar 

  18. Walsh DC, Kakkar AK: Thromboembolism in brain tumors. Curr Opin Pulm Med 2001, 7: 326–331. This is the most complete review of risk factors epidemiology, and outcome in patients with brain tumors and VTE.

    Article  PubMed  CAS  Google Scholar 

  19. Goldschmidt N, Linetsky E, Shalom E, et al.: High inci-dence of thromboembolism in patients with central ner-vous system lymphoma. Cancer 2003, 98: 1239–1242.

    Article  PubMed  Google Scholar 

  20. Streiff MB, Segal J, Grossman SA, et al.: ABO blood group is a potent risk factor for venous thromboem-bolism in patients with malignant gliomas. Cancer 2004, 100: 1717–1723.

    Article  PubMed  Google Scholar 

  21. Marras LC, Geerts WH, Perry JR: the risk of venous thromboembolism is increased throughout the course of malignant gliomas: an evidence-based review. Can-cer 2000, 89: 640–646.

    CAS  Google Scholar 

  22. Bates SM, Kearon C, Crowther M, et al.: A diagnostic strategy involving a quantitative latex D-dimer assay reliably excludes deep venous thrombosis. Ann Intern Med 2003, 138: 787–794.

    PubMed  Google Scholar 

  23. Stein PD, Hull RD, Patel KC, et al.: D-Dimer for the exclusion of acute venous thrombosis and pulmonary embolism. Ann Intern Med 2004, 140: 589–602.

    PubMed  Google Scholar 

  24. Kruip MJHA, Leclercq MGL, Van der Heul C, et al.: Diag-nostic strategies for excluding pulmonary embolism in clinical outcome studies. Ann Intern Med 2003, 138: 941–951.

    PubMed  Google Scholar 

  25. Stevens SM, Elliott CG, Chan KJ, et al.: Withholding anti-coagulation after a negative result on duplex ultrasonog-raphy for suspected symptomatic deep venous thrombosis. Ann Intern Med 2004, 140: 985–991.

    PubMed  Google Scholar 

  26. Macdonald RL, Amidei C, Lin G, et al.: Safety of periop-erative subcutaneous heparin for prophylaxis of venous thromboembolism in patients undergoing craniotomy. Neurosurgery 1999, 45: 245–251.

    Article  PubMed  CAS  Google Scholar 

  27. Goldhaber SZ, Dunn K, Gerhard-Herman AM, et al.: Low rate of venous thromboembolism after craniot-omy for brain tumor using multimodality prophy-laxis. Chest 2002, 122: 1933–1937.

    Article  PubMed  Google Scholar 

  28. Agnelli G, Piovella F, Buonocristiani P, et al.: Enoxaparin plus compressive stockings compared with compres-sive stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998, 339: 80–85. This is a good Class I study showing the benefit of LMWH over compressive stockings alone.

    Article  PubMed  CAS  Google Scholar 

  29. Iorio A, Agnell G: Low molecular weight and unfrac-tionated heparin for prevention of venous throm-boembolism in neurosurgery. Arch Intern Med 2000, 160: 2327–2332. This is a fine meta-analysis of all LMWHs and strongly makes the case for their use in neurosurgical patients, most of whom had brain tumors.

    Article  PubMed  CAS  Google Scholar 

  30. Gerlach R, Scheuer T, Beck J, et al.: Risk of postoperative hemorrhage after intracranial surgery post early nadroparin administration: results of a prospective study. Neurosurgery 2003, 53: 1028–1035.

    Article  PubMed  Google Scholar 

  31. Leizorovicz A, Goldhaber S: Prospective evaluation of dalteparin efficacy in immobilized patients trial (PRE-VENT) presented at the Society of Critical Care Medi-cine’s 32nd Annual Critical Care Congress. http:// www.theheart.org/index.cfm

  32. Carman TL, Kanner AA, Barnett GH, Deitcher SR: Pre-vention of thromboembolism after neurosurgery for brain and spinal tumors. South Med J 2003, 96: 17–22.

    Article  PubMed  Google Scholar 

  33. Schulman S: Care of patients receiving long-term anti-coagulant therapy. N Engl J Med 2003, 349: 675–683.

    Article  PubMed  Google Scholar 

  34. Tapson VF, Carroll BA, Davidson BL, et al.: The diagnos-tic approach to acute venous thromboembolism. Clinical practice guidelines. American Thoracic Soci-ety. Am J Respir Crit Care Med 1999, 60: 1043–1066.

    Google Scholar 

  35. Myers TM, Agnelli G, Hull RD, et al.: Antithrombotic therapy for venous thromboembolic disease. Chest 2001, 119(Suppl): S176–193.

    Article  Google Scholar 

  36. Bates SM, Ginsberg JS: Treatment of deep-vein throm-bosis. N Engl J Med 2004, 268–277. This is a fine review of DVT for patients with all medical and surgical illnesses. It also covers emerging antithrombin agents.

  37. Geerts WH, Heit JA, Clagett GP, et al.: Prevention of thromboembolism (Sixth ACCP Consensus Confer-ence on Antithrombotic Therapy.) Chest 2001, 119(Suppl): S132–1175.

    Article  Google Scholar 

  38. Levin JM, Schiff D, Loeffler JS, et al.: Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 1993, 43: 1111–1114.

    PubMed  CAS  Google Scholar 

  39. Wen PY, Marks PW: Medical management of patients with brain tumors. Curr Opinion Oncol 2002, 14: 299–307.

    Article  Google Scholar 

  40. Lee AYY, Levine MN, Baker RI, et al.: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003, 349: 146–153. This study convincingly shows the equal safety and superior efficacy of LMWH over warfarin in the prevention of recurrent VTE in patients with cancer, 5% of whom had brain tumors.

    Article  PubMed  CAS  Google Scholar 

  41. Meyer G, Marjanovic Z, Valcke J, et al.: Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002, 162: 1729–1735.

    Article  PubMed  CAS  Google Scholar 

  42. Knovich MA, Lesser GJ: The management of thrombem-bolic disease in patients with central nervous system malignancies. Curr Treat Option Oncol 2004, 5: 511–517. This is an excellent overview of LMWHs and other therapeutic strategies, specifically in the brain tumor population.

    Google Scholar 

  43. Cooper MS, Stewart PM: Corticosteroid insufficiency in acute ill patients. N Engl J Med 2003, 348: 727–734.

    Article  PubMed  CAS  Google Scholar 

  44. Coursin DB, Wood KE: Corticosteroid supplementation for adrenal insufficiency. JAMA 2002, 287: 236–239.

    Article  PubMed  CAS  Google Scholar 

  45. Luce JM: Editorial: Physicians should administer low-dose corticosteroids selectively to septic patients until an ongoing trial is completed. Ann Intern Med 2004, 141: 70–72.

    PubMed  CAS  Google Scholar 

  46. Cestari DM, Weine DM, Oanageas KS, et al.: Stroke in patients with cancer: incidence and etiology. Neurology 2004, 62: 2025–2030.

    PubMed  CAS  Google Scholar 

  47. Hariharan S, Shapiro W, Chang S, et al.: Phase II ran-domized dose-ranging trial of human corticotrophin releasing factor in symptomatic brain tumor patients. Neurology 2000, 54: A12.

    Google Scholar 

  48. French JA, Kanner AM, Bautista J, et al.: Efficacy and tol-erability of the new antiepileptic drugs I: treatment of new onset epilepsy. Neurology 2004, 62: 1252–1260; 1261–1273. This is the most complete compendium of information about the newer AEDs.

    PubMed  CAS  Google Scholar 

  49. Mamon H, Wen PY, Burns A, et al.: Allergic skin reac-tions to anticonvulsant medications in patients receiving cranial radiation. Epilepsia 1999, 40: 31–344.

    Article  Google Scholar 

  50. Mattson RH: Cognitive, affective, and behavioral side effects in adults secondary to antiepileptic drug use. Rev Neurol Dis 1(Suppl 1):S10-16. This article does not specifically address patients with brain tumors; an article in the same issue by Bromfield [17] in sup-plements the discussion for patients with brain tumors.

  51. Fugh-Berman AL: Herb-drug interactions. Lancet 2000, 355: 1019–1020.

    Google Scholar 

  52. Weiger WA, Smith M, Boon H, et al.: Advising patients who seek complementary and alternative medical thera-pies for cancer. Ann Intern Med 2002, 137: 889–903.

    PubMed  Google Scholar 

  53. Cesarone MR, Belcaro G, Nicolaides AN, et al.: Venous thrombosis from air travel: the LONFLIT3 study-Pre-vention with aspirin vs. low-molecular-weight heparin in high-risk subjects. A randomized trial. Angiology 2002, 53: 1–6.

    Article  Google Scholar 

  54. Chan AT, Atiemo A, Diran LK, et al.: Venous throm-boembolism occurs frequently inpatients undergoing brain tumor surgery despite prophylaxis. J Thomb Thrombolysis 1999, 8: 139–142.

    Article  CAS  Google Scholar 

  55. Buller HR, Davidson BL, Decousus H, et al.: Fonda-parinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. Ann Intern Med 2004, 140: 867–873.

    PubMed  Google Scholar 

  56. Francis CW, Ginsberg JS, Berkowitz SD, et al.: Efficacy and safety of the oral direct thrombin inhibitor ximel-agatran compared with current standard therapy for acute symptomatic deep vein thrombosis with or without pulmonary embolism: the THRIVE Treatment Study. Blood 2003, 102: 6a.

    Google Scholar 

  57. Schulman S, Wahlander K, Lundstrom T, et al.: Second-ary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelgatran. N Engl J Med 2003, 349: 1713–1721.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Pennsylvania, 3400 Spruce Street, 19104, Philadelphia, PA, USA

    Amy A. Pruitt MD

Authors
  1. Amy A. Pruitt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pruitt, A.A. Treatment of medical complications in patients with brain tumors. Curr Treat Options Neurol 7, 323–336 (2005). https://doi.org/10.1007/s11940-005-0042-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-005-0042-y

Keywords

Search

Navigation